MAPT and early-onset autosomal dominant Alzheimer disease: Optical sensors can utilize fluorescence or surface plasmonic resonance (SPR) signal changes to monitor the concentrations of Aβ and tau proteins in real-time during the treatment of Alzheimer’s disease patients, thereby providing a basis for evaluating treatment effects.